Want to see AQST full AI Analyst Report?
AQST Stock Chart & Stats
$4.32
-$0.11(-3.57%)
At close: 4:00 PM EST
$4.32
-$0.11(-3.57%)
Day’s Range― - ―
52-Week Range$2.93 - $7.55
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.96M
Market Cap
$531.98M
Enterprise Value$462.77M
Total Cash (Recent Filing)$110.73M
Total Debt (Recent Filing)$133.58M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 04, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding125,466,990
10 Day Avg. Volume2,437,445
30 Day Avg. Volume1,963,388
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)-23.41
Price to Sales (P/S)17.69
P/FCF Ratio-14.87
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue9.21
Enterprise Value/Gross Profit14.51
Enterprise Value/Ebitda-8.96
Forecast
1Y Price Target
$8.57Price Target Upside98.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$50.58M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward Anaphylm ResubmissionA completed Type A meeting and submitted human factors protocol create a clearer regulatory pathway for Anaphylm. This reduces program uncertainty, focuses the company's near-term development activities, and sets a realistic timeline (Q3 2026 resubmission) for potential approval and commercialization over the next several months.
Materially Strengthened Liquidity And Financing FlexibilityThe $150M Oaktree facility plus ~$110M cash materially extends runway into and through launch, lowering near-term principal payments and providing optionality for study execution, commercial build, and regulatory work. This reduces near-term refinancing risk and supports execution of the launch plan.
Commercial And Medical Affairs Launch PreparationBuilding a sizable sales force, expanded medical affairs, and rising HCP awareness indicate durable commercial readiness. These investments improve the company's ability to drive adoption, manage payer/hub interactions, and convert awareness into prescriptions if approval occurs, supporting sustainable revenue execution.
Bears Say
Persistent Negative Cash Flow And Cash BurnSustained negative operating and free cash flow increases dependence on external financing and heightens liquidity risk if milestones slip. Continued cash burn constrains reinvestment, forces prioritization of projects, and raises the probability of dilution or restricted growth absent successful product approvals or partner revenues.
Negative Stockholders' Equity And Weakened Balance SheetMaterially negative equity signals accumulated losses and limits financial flexibility. Even with reduced debt, negative equity can make future financing more costly or dilutive, reduce lender confidence, and amplify vulnerability to adverse events—persisting as a structural constraint on strategic options.
FDA CRL Requiring New Human Factors And PK StudiesThe CRL-imposed studies add time, cost, and execution risk before approval. These requirements make resubmission timing dependent on FDA feedback and study outcomes, delay potential revenue realization, and can affect access to conditional financing tranches—raising medium-term approval and launch uncertainty.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics, Inc.’s price range in the past 12 months?
Aquestive Therapeutics, Inc. lowest stock price was $2.93 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics, Inc.’s market cap?
Aquestive Therapeutics, Inc.’s market cap is $531.98M.
When is Aquestive Therapeutics, Inc.’s upcoming earnings report date?
Aquestive Therapeutics, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 24 days.
How were Aquestive Therapeutics, Inc.’s earnings last quarter?
Aquestive Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.064.
Is Aquestive Therapeutics, Inc. overvalued?
According to Wall Street analysts Aquestive Therapeutics, Inc.’s price is currently Undervalued.
Does Aquestive Therapeutics, Inc. pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
What is Aquestive Therapeutics, Inc.’s EPS estimate?
Aquestive Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has 125,466,990 shares outstanding.
What happened to Aquestive Therapeutics, Inc.’s price movement after its last earnings report?
Aquestive Therapeutics, Inc. reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 14.528%.
Which hedge fund is a major shareholder of Aquestive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.57 (98.41% Upside)
$8.57 (98.41% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 775.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.73%
12-Months-Change
Fundamentals
Return on Equity
190.87%
Trailing 12-Months
Asset Growth
38.04%
Trailing 12-Months
Company Description
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple strong positives: substantive regulatory progress, a completed Phase I safety study with promising directional biomarkers for AQST-108, materially improved Q1 financials (revenues +66%, sharply reduced net loss and non-GAAP EBITDA loss), a strengthened liquidity position via a $150M Oaktree facility and RTW extension, and active commercial and medical affairs preparations (75-person sales force plan, conference/publication program). The primary negatives are the existing FDA CRL requirements (human factors and PK studies) that make resubmission timing dependent on FDA responses, expected challenges around payer coverage and physician-office friction at launch, the one-time nature of a portion of Q1 royalty revenue, and conditional access to some debt tranches. Overall, the positives (regulatory path clarity in progress, improved financials, strong liquidity, promising pipeline signal, and concrete launch planning) outweigh the risks and remaining obstacles, though execution on studies, FDA timelines, and market access remain critical.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.57
▲(98.41% Upside)
Technical Analysis
Emergent Biosolutions
―
SIGA Technologies
―
Esperion
―
Organogenesis Holdings
―
Evolus
―
Ownership Overview
2.30% Insiders
9.17% Mutual Funds
1.27% Other Institutional Investors
78.09% Public Companies and
Individual Investors